

ORIGINAL ARTICLES (PEER REVIEWED)

Impact factors (IF) according to the latest Journal Citation Reports® Science Edition 2024

1. Brook GA, Houweling DA, Gieling RG, **Hermanns T**, Joosten EA, Bär DP, Gispén WH, Schmitt AB, Leprince P, Noth J, Nacimient W (2000)
Attempted endogenous tissue repair following experimental spinal cord injury in the rat: involvement of cell adhesion molecules L1 and N-CAM?
Eur J Neurosci. 12(9): 3224-38
Impact factor: 2.4
2. **Hermanns T**, Sulser T, Fatzer M, Baumgartner MK, Rey JM, Sigrist MW, Seifert HH (2009)
Laser fibre deterioration and loss of power output during photo-selective 80-W potassium-titanyl-phosphate laser vaporisation of the prostate.
Eur Urol. 55(3): 679-85
Impact factor: 25.2
3. Baumgartner MK, **Hermanns T**, Cohen A, Schmid DM, Seifert B, Sulser T, Strebel RT (2008)
Patient's knowledge about risk factors for erectile dysfunction is poor.
J Sex Med. 5(10): 2399-404
Impact factor: 3.3
4. Sørensen KD, Wild PJ, Mortezaei A, Adolf K, Tørring N, Heebøll S, Uthøi BP, Ottosen P, Sulser T, **Hermanns T**, Moch H, Borre M, Ørntoft TF, Dyrskjøl L (2009)
Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
Clin Cancer Res. 15(4): 1400-10
Impact factor: 10.2
5. **Hermanns T**, Sauermann P, Rufibach K, Frauenfelder T, Sulser T, Strebel RT (2009)
Is there a role for Tamsulosin in the treatment of distal ureteral stones of 7mm or less? Results of a randomised, double-blind, placebo-controlled trial.
Eur Urol. 56(3): 407-12
Impact factor: 25.2

6. Wild PJ, Fuchs T, Stoehr R, Zimmermann D, Frigerio S, Padberg B, Steiner I, Zwarthoff EC, Burger M, Denzinger S, Hofstaedter F, Kristiansen G, **Hermanns T**, Seifert HH, Provenzano M, Sulser T, Roth V, Buhmann JM, Moch H, Hartmann A (2009)
Detection of urothelial bladder cancer cells in voided urine can be improved by a combination of cytology and standardized microsatellite analysis.
Cancer Epidemiol Biomarkers Prev. 18(6): 1798-806
Impact factor: 3.4
7. Tischler V, Fritzsche R, Wild PJ, Stefan C, Seifert HH, Riener MO, **Hermanns T**, Gerhardt J, Schraml P, Jung K, Moch H, Soltermann A, Kristiansen G (2010)
Periostin is up-regulated in high grade and high stage prostate cancer.
BMC Cancer. 10: 273-81
Impact factor: 3.4
8. Ikenberg K, Fritzsche FR, Zuerrer-Haerdi U, Hofmann I, **Hermanns T**, Seifert H, Müntener M, Provenzano M, Sulser T, Behnke S, Gerhardt J, Mortezaei A, Wild P, Hofstädter F, Burger M, Moch H, Kristiansen G (2010)
Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores.
BMC Cancer. 10: 341-6
Impact factor: 3.4
9. Mortezaei A, **Hermanns T**, Seifert HH, Baumgartner MK, Provenzano M, Sulser T, Burger M, Hofstädter F, Krek W, Hartmann A, Moch H, Kristiansen G, Wild PJ (2011)
KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
Clin Cancer Res. 17(5): 1111-21
Impact factor: 10.2
10. Gerhardt J, Steinbrech C, Büchi O, Behnke S, Bohnert A, Fritzsche FR, Wild PJ, Schraml P, **Hermanns T**, Müntener M, Kristiansen G (2011)
The androgen-regulated calcium-activated nucleotidase 1 is strongly overexpressed in prostate cancer and is tumorbiologically relevant in vitro.
Am J Pathol. 178(4): 1847-60
Impact factor: 3.6

11. **Hermanns T**, Strebel DD, Hefermehl LJ, Gross O, Mortezaavi A, Müller A, Eberli D, Müntener M, Michel MS, Meier AH, Sulser T, Seifert HH (2011)
Lithium triborate-laser vaporisation of the prostate using the 120W, high performance system laser: high performance all the way?
J Urol. 185(6): 2241-7
Impact factor: 6.8
12. Beer M, Montani M, Gerhardt J, Wild PJ, Hany T, **Hermanns T**, Müntener M, Kristiansen G (2012)
Profiling gastrin releasing peptide receptor in prostate tissues: clinical implications and molecular correlates.
Prostate. 72(3): 318-25
Impact factor: 2.5
13. Von Boehmer L, Keller L, Mortezaavi A, Provenzano M, Sais G, **Hermanns T**, Sulser T, Jungbluth AA, Old LJ, Kristiansen G, van den Broek M, Moch H, Knuth A, Wild PJ (2011)
MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer.
PLoS One. 6(7); e21366
Impact factor: 2.6
14. Gerhardt J, Montani M, Wild PJ, Beer M, Huber F, **Hermanns T**, Müntener M, Kristiansen G (2012)
FoxA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castrate resistant prostate cancer.
Am J Pathol. 180(2): 848-61
Impact factor: 3.6
15. Beermann A, Ghanjati F, **Hermanns T**, Poyet C, Fischer PJ, Wernet P, Santourlidis S (2011)
Methods for Separate Isolation of Cell-Free DNA and Cellular DNA from Urine-Application of Methylation-Specific PCR on both DNA Fractions
The Open Biomarker J. 4: 15-17
Impact factor: n/a
16. Mortezaavi A, **Hermanns T**, Seifert HH, Wild PJ, Schmid DM, Sulser T, Eberli D (2012)
Intrafascial dissection significantly increases positive surgical margin and biochemical recurrence rates after robotic assisted radical prostatectomy.
Urol Int. 26: 17-24
Impact factor: 1.3

17. Boysen G, Bausch-Fluck D, Thoma CR, Novicka AM, Stiehl DP, Cima IL, Luu V, von Teichman A, **Hermanns T**, Sulser T, Ingold-Heppner B, Fankhauser N, Wenger RH, Krek W, Schraml P, Wollscheid B, Moch H (2012)
Relative quantification of the renal carcinoma surfaceome reveals pVHL-dependent cell surface glycoproteins as clinical markers.
Neoplasia. 14(6): 535-46
Impact factor: 7.7

18. Montani M, **Hermanns T**, Müntener M, Wild P, Sulser T, Kristiansen G (2013)
Multidrug resistance protein 4 (MRP4) expression in prostate cancer is associated with androgen signalling and decreases with tumor progression.
Virchows Arch. 463(1): 437-46
Impact factor: 3.1

19. Kaufmann MR, Schraml P, **Hermanns T**, Wenger RH, Camenisch G (2013)
Onconeural antigen Cdr2 correlates with HIF prolyl-4-hydroxylase PHD1 and worse prognosis in renal cell carcinoma.
Exp Mol Pathol. 94(3): 453-457
Impact factor: 3.7

20. Mortezaei A, **Hermanns T**, Hefermehl LJ, Spahn D, Seifert B, Weber DR, Schmid DM, Sulser T, Eberli D (2013)
Continuous anti-platelet therapy in robotic-assisted laparoscopic radical prostatectomy.
J Laparoendosc Adv Surg Tech A. 23(6): 500-5
Impact factor: 1.1

21. Dannenmann SR, Thielicke J, Stöckli M, Matter C, von Boehmer L, Cecconi V, **Hermanns T**, Hefermehl L, Schraml PH, Moch H, Knuth A, van den Broek M (2013)
Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma.
Oncoimmunology. 2(3): e23562
Impact factor: 6.3

22. **Hermanns T**, Fankhauser CD, Hefermehl LJ, Kranzbühler B, Wong LM, Capol JC, Zimmermann M, Sulser T, Müller A (2013)
Prospective evaluation of irrigation fluid absorption during pure transurethral bipolar plasma vaporisation of the prostate using expired breath ethanol measurements.
BJU Int. 112(5): 647-54
Impact factor: 4.4

23. Kranzbühler B, Wettstein MS, Fankhauser CD, Grossmann NC, Gross O, Poyet C, Largo R, Fischer B, Zimmermann M, Sulser T, Müller A, **Hermanns T** (2013)
Pure bipolar plasma vaporization of the Prostate: The Zürich experience.
J Endourol. 27(10): 1261-6
Impact factor: 2.8
24. Hefermehl LJ, Largo R, **Hermanns T**, Poyet C, Sulser T, Eberli D (2013)
Lateral temperature spread of monopolar, bipolar and ultrasonic instruments for robotic assisted laparoscopic surgery.
BJU Int. 114(2): 245-52
Impact factor: 4.4
25. **Hermanns T**, Gross O, Kranzbühler B, Hefermehl LJ, Poyet C, Fankhauser CD, Müller A, Yap SA, Michel MS, Eberli A, Müntener M, Zimmermann M, Sulser T, Seifert HH (2013)
Ablative efficiency of 532 nm laser vaporization compared to transurethral resection of the prostate: Results from a prospective three-dimensional ultrasound volumetry study.
World J Urol. 32(5): 1267-74
Impact factor: 2.9
26. Poyet C, Jentsch B, **Hermanns T**, Schweckendieck D, Seifert HH, Schmidtpeter M, Sulser T, Moch H, Wild PJ, Kristiansen G (2014)
Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer.
BMC Clin Pathol. 14(1): 10
Impact factor: n/a
27. Dannenmann SR, **Hermanns T**, Bransi A, Matter C, von Boehmer L, Stevanovic S, Schraml PH, Moch H, Knuth A, van den Broek M (2013)
Spontaneous peripheral T cell responses towards the tumor-associated antigen Cyclin D1 in patients with clear cell renal cell carcinoma.
Cancer Immunol Res. 1(5): 288-95
Impact factor: 8.2
28. Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, **Hermanns T**, Šeruga B, Ocaña A, Tannock IF, Amir E (2014)
Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis.
Cancer Epidemiol Biomarkers Prev. 23(7): 1204-12
Impact factor: 3.4

29. **Hermanns T**, Bhindi B, Wei Y, Yu J, Noon AP, Richard PO, Bhatt JR, Almatar A, Jewett MAS, Fleshner NE, Zlotta AR, Templeton AJ, Kulkarni GS (2014) Pretreatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder.
Br J Cancer. 111(3): 444-51
Impact factor: 6.8
30. **Hermanns T**, Grossmann NC, Wettstein MS, Fankhauser CD, Capol JC, Poyet C, Hefermehl LJ, Zimmermann M, Sulser T, Müller A (2015) Absorption of irrigation fluid occurs frequently during high-power 523nm laser vaporization of the prostate.
J Urol. 193(1): 211-6
Impact factor: 6.8
31. Ghanjati F, Beermann A, **Hermanns T**, Poyet C, Araújo-Bravo MJ, Seifert HH, Schmidpeter M, Goering W, Sorg R, Wernet P, Santourlidis S (2014) Unreserved application of epigenetic methods to define differences of DNA methylation between urinary cellular and cell-free DNA.
Cancer Biomark. 14(5): 295-302
Impact factor: 1.9
32. Liu Y, Noon AP, Cabeza EA, Shen J, Kukc , Ilczynski C, Ni R, Sukhu B, Chan K, Barbosa-Morais NL, **Hermanns T**, Blencowe BJ, Azad A, van der Kwast TH, Catto JWF, Zlotta AR, Wrana JL (2014) Next generation RNA sequencing of archival formalin fixed paraffin embedded urothelial bladder cancer.
Eur Urol. 66(6): 982-6
Impact factor: 25.2
33. Richard PO, Abramsky H, Bhatt JR, **Hermanns T**, Hersey KM, Chadwick K, Habeeba B, Fleshner NE (2015) Impact of energy drinks on androgen deprivation induced fatigue: Results of a pilot study
J Caffeine Res. 5(1): 50-4
Impact factor: n/a

34. Ruf M, Fieger C, Hartmann A, **Hermanns T**, Poyet C, van den Broek M, Sulser T, Moch H, Schraml P (2015)
CD70 is upregulated via the pVHL-HIF α axis and triggers the release of the soluble form of its receptor CD27 from tumour infiltrating lymphocytes in renal cell carcinoma.
Clin Cancer Res. 21(4): 889-98
Impact factor: 10.2
35. Richard PO, Bhatt JR, **Hermanns T**, Juvet T, Manickavachagam K, Evans AJ, Kachura JR, Jewett MAS, Finelli A (2015)
The Outcome of Renal Tumor Biopsies for Small Renal Masses: A Single-Center 13-year Experience.
Eur Urol. 68(6): 1007-13
Impact factor: 25.2
36. Nayan M, Bhindi B, Yu JL, **Hermanns T**, Hamilton RJ, Finelli A, Jewett MAS, Zlotta AR, Fleshner NE, Kulkarni GS (2015)
The impact of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial carcinoma of the bladder.
Urol Oncol – Semin Ori. 33(9): 386 e7-13
Impact factor: 2.3
37. Benoit T, Keller E, Wolfsgruber P, **Hermanns T**, Günthart M, Banzola I, Sulser T, Provenzano M, Poyet C (2015)
High VEGF-D and low MMP-2 serum levels predict nodal positive disease in invasive bladder cancer.
Med Sci Monit. 21: 2266-74
Impact factor: 2.1
38. Poyet C, Buser L, Roudnicky F, Detmar M, **Hermanns T**, Mannhard D, Höhn A, Sulser T, Moch H, Wild PJ (2015)
Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer.
J Clin Pathol. 68(10): 819-24
Impact factor: 2.0

39. Poyet C, Nieboer D, Bhindi B, Kulkarni GS, Wiederkehr C, Largo R, Wild PJ, Sulser T, **Hermanns T** (2016)
Prostate cancer risk prediction using the updated ERSPC and PCPT risk calculators: Independent validation and comparison in a contemporary European cohort.
BJU Int. 117(3): 401-8
Impact factor: 4.4
40. Wettstein MS, Buser L, **Hermanns T**, Roudnicky F, Eberli D, Baumeister P, Sulser T, Wild P, Poyet C (2015)
CD73 predicts favourable prognosis in patients with non-muscle invasive urothelial bladder cancer.
Dis Markers. 2015: 785461
Impact factor: 3.46
41. Bhindi B, **Hermanns T***, Wei Y, Yu J, Templeton AJ, Richard PO, Wettstein MS, Shirdhar SS, Jewett MAS, Fleshner NE, Zlotta AR, Kulkarni GS (2016)
How to best use the complete blood count to predict oncologic outcomes following radical cystectomy for bladder cancer.
Br J Cancer. 114(2): 207-12
Impact factor: 6.8
42. Mortezaei A, Sulser T, Robbiani J, Drescher E, Disteldorf D, Eberli D, Poyet C, Baumgartner MK, Seifert HH, **Hermanns T** (2016)
Long-term oncological outcome of an initial series of laparoscopic radical prostatectomy for clinically localized prostate cancer after a median follow-up of 10 years.
Clin Genitourin Cancer. 14(4):290-7
Impact factor: 2.7
43. Poyet C, **Hermanns T**, Zhong Q, Eberli D, Burger M, Hofstaedter F, Hartmann A, Stöhr R, Zwarthoff EC, Sulser T, Wild PJ (2015)
Positive FGFR3 immunoreactivity defines low-grade urothelial bladder cancer.
Oncol Lett. 10(5): 2753-60
Impact factor: 2.2
44. Wettstein MS, Poyet C, Grossmann NC, Fankhauser CD, Keller XE, Kozomara M, Meyer S, Sulser T, Müller A, **Hermanns T** (2016)
Absorption of irrigation fluid during XPS™ GreenLight laser vaporization of the prostate: results from a prospective breath ethanol monitoring study.
World J Urol. Epub. ahead of print

Impact factor: 2.9

45. Santourlidis S, Ghanjati F, Beermann A, **Hermanns T**, Poyet C (2016)
IDLN-MSP - Idioloal normalization of real-time methylation-specific PCR for
genetic
imbalanced DNA specimens.
BioTechniques. 60(2): 84-7

Impact factor: 2.5

46. Nayan M, Bhindi B, Yu JL, Mamdani M, Fleshner NE, **Hermanns T**, Chung P,
Milosevic M, Bristow R, Warde P, Hamilton RJ, Finelli A, Jewett MAS, Zlotta
AR, Shridhar SS, Kulkarni GS (2016)
The initiation of a multidisciplinary bladder cancer clinic and the uptake of
neoadjuvant chemotherapy: A time-series analysis.
Can Urol Assoc J. 10(1-2): 25-30

Impact factor: 2.0

47. Mortezaei A, Keller EX, Poyet C, **Hermanns T**, Saba K, Randazzo M,
Fankhauser CD, Wild PJ, Moch H, Sulser T, Eberli D (2016)
Clinical impact of prostate biopsy undergrading in an academic and
community setting.
World J Urol. 34(10):1481-90

Impact factor: 2.9

48. Templeton AJ, Knox JJ, Lin X, Simantov R, Xie W, Mitchell N, Broom R, Fay
AP, Rini B, Donskov F, Bjarnason GA, Smoragiewicz M, Kollmannsberger C,
Kanesvaran R, Alimohamed N, **Hermanns T**, Wells C, Amir E, Choueiri TK,
Heng DYC (2016)
Change in neutrophil to lymphocyte ratio in response to targeted therapy
for metastatic renal cell carcinoma as a prognosticator and biomarker of
efficacy.
Eur Urol. 70(2):358-64.

Impact factor: 25.2

49. Fankhauser CD, Bode PK, **Hermanns T**, Sander S, Sulser T, Altevogt P,
Moch H, Tischler V (2016)
L1-CAM is commonly expressed in testicular germ cell tumors.
J Clin Pathol. 69(5):460-2.

Impact factor: 2.0

50. Poyet C, Wettstein MS, Lundon DJ, Bhindi B, Kulkarni GS, Saba K, Sulser T,
Vickers AJ, **Hermanns T** (2016)
External evaluation of a novel prostate cancer risk calculator
(ProstateCheck) based on data of the Swiss arm of the ERSPC.

J Urol. 196(5): 1402-7

Impact factor: 6.8

51. Kranzbühler B, Gross O, Fankhauser CD, Wettstein MS, Grossmann NC, Hefermehl LJ, Zimmermann M, Müller A, Eberli D, Sulser T, Poyet C, **Hermanns T** (2016)

Prostate volume reduction following pure transurethral bipolar plasma vaporization and conventional transurethral resection of the prostate: a prospective investigation using transrectal 3D ultrasound volumetry.

World J Urol. 35(3):429-435

Impact factor: 2.9

52. Wettstein MS, Saba K, Umbehre MH, Fankhauser CD, Adank JP, Hofmann M, Murtola T, Sulser T, **Hermanns T**, Wild PJ, Poyet C (2017)

Prognostic role of preoperative serum lipid levels in patients undergoing radical prostatectomy for clinically localized prostate cancer.

Prostate. 77(5):549-556

Impact factor: 2.5

53. Olkhov-Mitsel E, Savio AJ, Kron KJ, Pethe VV, **Hermanns T**, Fleshner NE, van Rhijn B, van der Kwast TH, Zlotta AR, Bapat B (2017)

Epigenome-wide DNA methylation profiling identifies differential methylation biomarkers in high grade bladder cancer.

Transl Oncol. 10(2):168-177

Impact factor: 4.1

54. Corro C, Hejhal T, Poyet C, Sulser T, **Hermanns T**, Winder T, Prager G, Wild PJ, Frew I, Moch H, Rechsteiner M (2017)

Detecting circulating tumor DNA in renal cancer: An open challenge.

Exp Mol Pathol. 102(2):255-261

Impact factor: 3.7

55. Zong Q, Guo T, Rechsteiner M, Rüschhoff JH, Rupp N, Fankhauser C, Saba K, Mortezaei A, Poyet C, **Hermanns T**, Zhu Y, Moch H, Aebersold R, Wild PJ (2017)

A comprehensive collection of tissue microarray images and clinical outcome data of prostate cancer patients.

Sci Data. 4:170014

Impact factor: 6.9

56. Kulkarni GS, **Hermanns T***, Wei Y, Bhindi B, Satkunasivam R, Athanasopoulos P, Bostrom PJ, Kuk C, Li K, Templeton AJ, Sridhar SS, van der Kwast TH, Chung P, Bristow RG, Milosevic M, Warde P, Fleshner NE, Jewett MAS, Bashir S, Zlotta AR (2017)
Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. J Clin Oncol. 35(20):2299-2305
Impact factor: 41.9

57. Mortezaei A, Salemi S, Rupp N, Rueschoff JH, **Hermanns T**, Poyet C, Randazzo M, Simon HU, Moch H, Sulser T, Wild PJ, Eberli D (2017)
Negative LC3b immunoreactivity in cancer cells is an independent prognostic predictor of prostate cancer specific death. Oncotarget. 8(19):31765-31774
Impact factor: 5.168

58. Bezan A, Posch F, Ploner F, Bauernhofer T, Pichler M, Szkandera J, Hutterer GC, Pummer K, Gary T, Samonigg H, Beyer J, Winder T, **Hermanns T**, Fankhauser CD, Gerger A, Stotz M (2017)
Risk stratification for venous thromboembolism in patients with testicular germ cell tumors. PloS one. 12(4):e0176283
Impact factor: 2.6

59. Bhindi B, Fleshner NE, Finelli A, Hamilton RJ, **Hermanns T**, Toi A, Poyet C, Zlotta AR, Jiang H, Evans A, van der Kwast T, Li K, Kulkarni GS (2017)
Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicion. Urol Oncol – Semin Ori. 35(10):604.e17-604.e24
Impact factor: 2.3

60. Mannil M, von Spiczak J, **Hermanns T**, Alkadhi H, Fankhauser CD (2017)
Prediction of successful shock wave lithotripsy with CT: a phantom study using texture analysis. Abdom Radiol (NY). 43(6):1432-1438
Impact factor: 2.2

61. Fankhauser CD, Sander S, Roth L, Beyer J, **Hermanns T** (2018)
Improved survival in metastatic germ-cell cancer. Ann Oncol. 29(2):347-351
Impact factor: 65.4

62. Erichsen L, Ghanjati F, Beermann A, Poyet C, **Hermanns T**, Schulz WA, Seifert HH, Wild PJ, Buser L, Kröning A, Braunstein S, Anlauf M, Jankowiak S, Hassan M, Bendhack ML, Bravo MA, Santourlidis S (2018)
Aberrant methylated key genes of methyl group metabolism within molecular etiology of urothelial carcinogenesis.
Sci Rep. 22;8(1):3477
Impact factor: 3.9
63. Mortezaei A, Märzendorfer O, Donati OF, Rizzi G, Rupp NJ, Wettstein MS, Gross O, Sulser T, **Hermanns T**, Eberli D (2018)
Diagnostic accuracy of mpMRI and fusion-guided targeted biopsy evaluated by transperineal template saturation prostate biopsy for the detection and characterization of prostate cancer.
J Urol. 200(2):309-318
Impact factor: 6.8
64. Fankhauser CD, Sander S, Roth L, Gross O, Eberli D, Sulser T, Seifert B, Beyer J, **Hermanns T**. (2018)
Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy.
Br J Cancer. 118(6):825-830
Impact factor: 6.8
65. Fankhauser CD, Schöffler PJ, Gillessen S, Omlin A, Rupp NJ, Rueschoff JH, **Hermanns T**, Poyet C, Sulser T, Moch H, Wild PJ (2017)
Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer.
Oncotarget. 9(12):10284-10293
Impact factor: 5.168
66. Mannil M, von Spiczak J, **Hermanns T**, Poyet C, Alkadhi H, Fankhauser CD (2018)
Three-Dimensional texture analysis with machine learning provides incremental predictive information for successful shock wave lithotripsy in patients with kidney stones.
J Urol. 200(4):829-836
Impact factor: 6.8

67. Fankhauser CD, Mohebbi N, Grogg J, Holenstein A, Zhong Q, **Hermanns T**, Sulser T, Steurer J, Poyet C (2018)
Prevalence of hypertension and diabetes after exposure to extracorporeal shock-wave lithotripsy in patients with renal calculi: a retrospective non-randomized data analysis.
Int Urol Nephrol. 50(7):1227-1233
Impact factor: 1.9
68. **Hermanns T**, Grossmann NC, Wettstein MS, Keller EX, Fankhauser CD, Gross O, Kranzbühler B, Lüscher M, Meier AH, Sulser T, Poyet C (2019)
Is loss of power output due to laser fiber degradation still an issue during prostate vaporization using the 180 W GreenLight XPS laser?
World J Urol. 37(1):181-187
Impact factor: 2.9
69. Fankhauser CD, **Hermanns T**, Lieger L, Diethelm O, Umbehre M, Luginbühl T, Sulser T, Müntener M, Poyet C (2018)
Extracorporeal shock wave lithotripsy versus flexible ureterorenoscopy in the treatment of untreated renal calculi.
Clin Kidney J. 11(3):364-369
Impact factor: 4,6
70. Arvaniti E, Fricker KS, Moret M, Rupp N, **Hermanns T**, Fankhauser C, Wey N, Wild PJ, Rüschhoff JH, Claassen M (2018)
Automated Gleason grading of prostate cancer tissue microarrays via deep learning.
Sci Rep. 8(1):12054
Impact factor: 3.9
71. Leão R, Lee D, Figueiredo A, **Hermanns T**, Wild P, Komosa M, Lau I, Mistry M, Nunes NM, Price AJ, Zhang C, Lipman T, Poyet C, Valtcheva N, Oehl K, Coelho H, Sayyid R, Gomes AM, Prado E Castro L, Sweet J, Vinagre J, Apolónio J, Stephens D, Faleiro I, Fadaak K, Richard PO, Kulkarni G, Zlotta AR, Hamilton RJ, Castelo-Branco P, Tabori U (2019)
Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behaviour of bladder cancer.
Int J Cancer. 144(7):1676-1684
Impact factor: 4.7

72. Lee DD, Leão R, Komosa M, Gallo M, Zhang CH, Lipman T, Remke M, Heidari A, Nunes NM, Apolónio JD, Price AJ, De Mello RA, Dias JS, Huntsman D, **Hermanns T**, Wild PJ, Vanner R, Zadeh G, Karamchandani J, Das S, Taylor MD, Hawkins CE, Wasserman JD, Figueiredo A, Hamilton RJ, Minden MD, Wani K, Diplas B, Yan H, Aldape K, Akbari MR, Danesh A, Pugh TJ, Dirks PB, Castelo-Branco P, Tabori U (2019)
DNA hypermethylation within TERT promoter upregulates TERT expression in cancer.
J Clin Invest.129(4):1801
Impact factor: 13.6
73. Keller EX, Bachofner J, Britschgi AJ, Saba K, Mortezaei A, Kaufmann B, Fankhauser CD, Wild P, Sulser T, **Hermanns T**, Eberli D, Poyet C (2018)
Prognostic value of unifocal and multifocal positive surgical margins in a large series of robot-assisted radical prostatectomy for prostate cancer.
World J Urol. 37(9):1837-44
Impact factor: 2.9
74. Tan WS, Ahmad A, Feber A, Mostafid H, Cresswell J, Fankhauser CD, Waisbrod S, **Hermanns T**, Sasieni P, Kelly JD; DETECT I trial collaborators. (2019)
Development and validation of a haematuria cancer risk score to identify patients at risk of harbouring cancer.
J Intern Med. 285(4):436-445
Impact factor: 9.2
75. **Hermanns T**, Gross O, Fankhauser CD, Wettstein MS, Grossmann NC, Keller EX, Eberli D, Sulser T, Poyet C, Kranzbühler B (2019)
Pure bipolar plasma vaporization of the prostate: 3-year results combining clinical mid-term outcome and 3D ultrasound volumetry data.
J Endourol. 33(2):107-112
Impact factor: 2.8
76. Bihl S, Ohashi R, Moore A, Rüschhoff J, Beisel C, **Hermanns T**, Mischo A, Corro C, Beyer J, Beerenwinkel J, Moch H, Schraml P (2019)
Expression and mutation patterns of PBRM1, BAP1 and SETD2 mirror specific evolutionary subtypes in clear cell Renal Cell Carcinoma.
Neoplasia. 21(2):247-256.
Impact factor: 7.7

77. Fankhauser CD, Gerke TA, Roth L, Sander S, Grossmann NC, Kranzbühler B, Eberli D, Sulser T, Beyer J, **Hermanns T** (2019)
Pre-orchietomy tumor marker levels should not be used for International Germ Cell Consensus Classification (IGCCCG) risk group assignment.
J Cancer Res Clin Oncol. 145(3):781-85
Impact factor: 2.8
78. Schraml P, Athelogou M, **Hermanns T**, Huss R, Moch H (2019)
Specific immune cell and lymphatic vessel signatures identified by image analysis in renal cancer.
Mod Pathol. 32(7):1042-52
Impact factor: 5.5
79. Dieckmann KP, Radtke A, Geczi L, Matthies C, Anheuser P, Eckardt U, Sommer J, Zengerling F, Trenti E, Pichler R, Belz H, Zastrow S, Winter A, Melchior S, Hammel J, Kranz J, Bolten M, Krege S, Haben B, Loidl W, Ruf CG, Heinzlbecker J, Heidenreich A, Cremers JF, Oing C, **Hermanns T**, Fankhauser CD, Gillessen S, Reichegger H, Cathomas R, Pichler M, Hentrich M, Eredics K, Lorch A, Wülfing C, Peine S, Wosniok W, Bokemeyer C, Belge G (2019)
Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.
J Clin Oncol. 37(16):1412-23
Impact factor: 41.9
80. Wettstein MS, Rooprai JK, Pazhepurackel C, Wallis CJD, Klaassen Z, Uleryk EM, **Hermanns T**, Fleshner NE, Zlotta AR, Kulkarni GS (2019)
Systematic review and meta-analysis on trimodal therapy versus radical cystectomy for muscle-invasive bladder cancer: Does the current quality of evidence justify definitive conclusions?
PLoS One. 29;14(4)
Impact factor: 2.6
81. Wettstein MS, Pazhepurackel C, Neumann AS, Woon DTS, Herrera-Caceres JO, Kozomara M, Poyet C, Sulser T, Kulkarni GS, **Hermanns T** (2019)
Photoselective vaporization of the prostate: study outcomes as a function of risk of bias, conflicts of interest and industrial sponsorship
World J Urol. 38(3):741-746
Impact factor: 2.9

82. Shao W, Guo T, Toussaint NC, Xue P, Wagner U, Li L, Charmpi K, Zhu Y, Wu J, Buljan M, Sun R, Rutishauser D, **Hermanns T**, Fankhauser CD, Poyet C, Ljubicic J, Rupp N, Rüschoff JH, Zhong Q, Beyer A, Ji J, Collins BC, Liu Y, Räscht G, Wild PJ, Aebersold R. (2019)
Comparative analysis of mRNA and protein degradation in prostate tissues indicates high stability of proteins
Nat Commun. 10(1):2524
Impact factor: 15.7
83. Kranzbühler B, Salemi S, Umbricht CA, Deberle LM, Müller C, Burger IA, **Hermanns T**, Sulser T, Eberli D (2019)
Concentration-dependent effects of dutasteride on prostate-specific membrane antigen (PSMA) expression and uptake of 177 Lu-PSMA-617 in LNCaP cells
Prostate. 79(12):1450-1456
Impact factor: 2.5
84. Hench IB, Cathomas R, Costa L, Fischer N, Gillessen S, Hench J, **Hermanns T**, Kremer E, Mingrone W, Mestre RP, Püschel H, Rothermundt C, Ruiz C, Tolnay M, Burg PV, Bubendorf L, Vlajnic T, Sakk SGFCCR. (2019)
Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial)
Cancers (Basel). 11(8):1099
Impact factor: 4.5
85. Fankhauser CD, Roth L, Grossmann NC, Kranzbühler B, Eberli D, Sulser T, Moch H, Bode PK, Beyer J, **Hermanns T**. (2019)
CXCL12 expression is an adverse predictor for disease recurrence in patients with metastatic non-seminomatous testicular germ cell tumors
BMC Cancer 14;19(1):802
Impact factor: 3.4
86. Ferraro DA, Muehlematter UJ, Garcia Schüler HI, Rupp NJ, Huellner M, Messerli M, Rüschoff JH, Ter Voert EEGW, **Hermanns T**, Burger IA (2019)
68 Ga-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancer
Eur J Nucl Med Mol Imaging. 47(1):147-159
Impact factor: 7.6

87. Schmid FA, Wettstein MS, Kessler TM, **Hermanns T**, Boss A, Hötter AM, Eberli D (2019)
Contrast media kinetics in multiparametric magnetic resonance imaging before radical prostatectomy predicts the probability of postoperative incontinence
World J Urol. 38(7):1741-48
Impact factor: 2.9
88. Grogg JB, Schneider K, Bode PK, Wettstein MS, Kranzbühler B, Eberli D, Sulser T, Beyer J, **Hermanns T**, Fankhauser CD (2019)
A Systematic Review of Treatment Outcomes in Localised and Metastatic Spermatocytic Tumors of the Testis
J Cancer Res Clin Oncol. 145(12):3037-45
Impact factor: 2.8
89. Lebentrau S, Wolff I, Hempel MC, Haccius M, Kluth LA, Pycha A, Brookman-May S, Schneider TR, **Hermanns T**, Distler FA, Boegemann M, Kübler H, Shariat SF, Burger M, May M (2019)
Knowledge of German-speaking urologists regarding the association between penile cancer and human papilloma virus: results of a survey of the European PROspective Penile Cancer Study (E-PROPS)
Aktuelle Urol doi: 10.1055
Impact factor: 0.4
90. Tran B, Ruiz-Morales JM, Gonzalez-Billalabeitia E, Patrikidou A, Amir E, Seidel C, Bokemeyer C, Fankhauser C, **Hermanns T**, Rumyantsev A, Tryakin A, Brito M, Fléchon A, Kwan EM, Cheng T, Castellano D, Garcia Del Muro X, Hamid AA, Ottaviano M, Palmieri G, Kitson R, Reid A, Heng DY, Bedard PL (2020)
Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)
Cancer Med. 9(1):116-24
Impact factor: 3.1
91. Ferraro DA, Garcia Schüler HI, Muehlematter UJ, Eberli D, Müller J, Müller A, Gablinger R, Kranzbühler H, Omlin A, Kaufmann PA, **Hermanns T***, Burger IA (2020)
Impact of 68 Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer
Eur J Nucl Med Mol Imaging. 47(3):652-664
Impact factor: 7.6

92. Fankhauser CD, Grogg JB, Hayoz S, Wettstein MS, Dieckmann KP, Sulser T, Bode PK, Clarke NW, Beyer J, **Hermanns T** (2020)
Risk Factors and Treatment Outcomes of 1,375 Patients with Testicular Leydig Cell Tumors: Analysis of Published Case Series Data
J Urol. 203(5):949-56.
Impact factor: 6.8
93. Grogg J, Schneider K, Bode PK, Kranzbühler B, Eberli D, Sulser T, Lorch A, Beyer J, **Hermanns T**, Fankhauser CD (2020)
Sertoli Cell Tumors of the Testes: Systematic Literature Review and Meta-Analysis of Outcomes in 435 Patients
Oncologist 25(7):585-59
Impact factor: 4.2
94. **Hermanns T**, Savio AJ, Olkhov-Mitsel E, Mari A, Wettstein MS, Saba K, Bhindi B, Kuk C, Poyet C, Wild PJ, Noon A, Bashir S, Juvet T, Rendon RA, Waltregny D, van der Kwast T, Finelli A, Kulkarni GS, Fleshner NE, Lo K, Bapat B, Zlotta AR (2020)
A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade
Urol Oncol Semin Ori 38(6):603.e1-e7
Impact factor: 2.3
95. Erichsen L, Seifert HH, Schulz WA, Hoffmann MJ, Niegisch G, Araújo-Bravo MJ, Bendhack ML, Poyet C, **Hermanns T**, Beermann A, Hassan M, Theis L, Mahmood W, Santourlidis S (2020)
Basic Hallmarks of Urothelial Cancer Unleashed in Primary Uroepithelium by Interference with the Epigenetic Master Regulator ODC1
Sci Rep. 10(1):3808
Impact factor: 3.9
96. Wettstein MS, Naimark D, **Hermanns T**, Herrera-Caceres JO, Ahmad A, Jewett MAS, Kulkarni G (2020)
Required efficacy for novel therapies in BCG-unresponsive non-muscle invasive bladder cancer: Do current recommendations really reflect clinically meaningful outcomes?
Cancer Med. 9(10):3287-96
Impact factor: 3.1

97. Fankhauser CD, Waisbrod S, Fierz C, Becker AS, Kranzbühler B, Eberli D, Sulser T, Mostafid H, **Hermanns T**. (2020)
Diagnostic accuracy of ultrasonography, computed tomography, cystoscopy and cytology to detect urinary tract malignancies in patients with asymptomatic hematuria World J Urol. 39(1):97-103.
Impact factor: 2.9
98. Seidel C, Daugaard G, Nestler T, Tryakin A, Fedyanin M, Fankhauser C, **Hermanns T**, Aparicio J, Heinzlbecker J, Paffenholz P, Heidenreich A, De Giorgi U, Cathomas R, Lorch A, Fingerhut A, Gayer F, Bremmer F, Giannatempo P, Necchi A, Aurilio G, Casadei C, Tran B, Dieckmann KP, Brito M, Ruf C, Oing C, Bokemeyer C (2020)
Human chorionic gonadotropin-positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3)
Eur J Cancer. 132:127-135
Impact factor: 7.1
99. Bieri U, Hübel K, Seeger H, Kulkarni GS, Sulser T, **Hermanns T**, Wettstein MS (2020)
Management of Active Surveillance-eligible Prostate Cancer during Pre-transplantation Work-up of Patients with Kidney Failure: A Simulation Study Clin J Am Soc Nephrol. 15(6):822-829.
Impact factor: 7.1
100. Ferraro DA, Rüschoff JH, Muehlematter UJ, Kranzbühler B, Müller J, Messerli M, Husmann L, **Hermanns T**, Eberli D, Rupp NJ, Burger IA (2020)
Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with 68 Ga-PSMA-11-PET
Theranostics. 10(14):6082-6094
Impact factor: 13.3
101. Wyvekens N, Valtcheva N, Mischo A, Helmchen B, **Hermanns T**, Choschzick M, Hötter AM, Rauch A, Mühleisen B, Akhoundova D, Weber A, Moch H, Rupp NJ (2020)
Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach
Genes Chromosomes Cancer. 2020 Nov;59(11):611-619
Impact factor: 2.8

102. Gallo A, Fankhauser C, **Hermanns T**, Beyer J, Christiansen A, Moch H, Bode PK (2020)
HNF1 β is a sensitive and specific novel marker for yolk sac tumor: a tissue microarray analysis of 601 testicular germ cell tumors
Mod Pathol. 33(11):2354-2360
Impact factor: 5.5
103. Fankhauser CD, Penney KL, Gonzalez-Feliciano AG, Clarke NW, **Hermanns T**, Stopsack KH, Fiorentino M, Loda M, Mahal B, Gerke TA, Preston MA, Mucci LA (2020)
Inferior Cancer Survival for Men with Localized High-grade Prostate Cancer but Low Prostate-specific Antigen
Eur Urol. 78(4):637-639.
Impact factor: 25.2
104. Fankhauser CD, Roth L, Kranzbühler B, Eberli D, Bode P, Moch H, Oliveira P, Ramani V, Beyer J, **Hermanns T** (2020)
The Role of Frozen Section Examination During Inguinal Exploration in Men with Inconclusive Testicular Tumors: A Systematic Review and Meta-analysis
Eur Urol Focus. S2405-4569(20)30185-1
Impact factor: 5.6
105. Grogg JB, Schneider K, Bode PK, Kranzbühler B, Eberli D, Sulser T, Beyer J, Lorch A, **Hermanns T**, Fankhauser CD (2020)
Risk Factors and Treatment Outcomes of 239 Patients with Testicular Granulosa Cell Tumors: A Systematic Review of Published Case Series Data
J Cancer Res Clin Oncol. 146(11):2829-2841
Impact factor: 2.8
106. Fankhauser CD, Wettstein MS, Reinhardt M, Gessendorfer A, Mostafid H, **Hermanns T**. (2020)
Indications and Complications of Androgen Deprivation Therapy
Semin Oncol Nurs. 36(4):151042
Impact factor: 2.5

107. Fankhauser CD, Tran B, Pedregal M, Ruiz-Morales JM, Gonzalez-Billalabeitia E, Patrikidou A, Amir E, Seidel C, Bokemeyer C, **Hermanns T**, Rummyantsev A, Tryakin A, Brito M, Fléchon A, Kwan EM, Cheng T, Castellano D, Del Muro XG, Hamid AA, Ottaviano M, Palmieri G, Kitson R, Reid A, Heng DYC, Bedard PL, Sweeney CJ, Connors JM. (2020)
A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy
Eur Urol Focus. S2405-4569(20)30280-7
Impact factor: 5.6
108. Charmpi K, Guo T, Zhong Q, Wagner U, Sun R, Toussaint NC, Fritz CE, Yuan C, Chen H, Rupp NJ, Christiansen A, Rutishauser D, Rüschoff JH, Fankhauser C, Saba K, Poyet C, **Hermanns T**, Oehl K, Moore AL, Beisel C, Calzone L, Martignetti L, Zhang Q, Zhu Y, Martínez MR, Manica M, Haffner MC, Aebbersold R, Wild PJ, Beyer A. (2020)
Convergent network effects along the axis of gene expression during prostate cancer progression
Genome Biol. 2020 Dec 14;21(1):302
Impact factor: 9.4
109. Ferraro DA, Lehner F, Becker AS, Kranzbühler B, Kudura K, Mebert I, Messerli M, **Hermanns T**, Eberli D, Burger IA (2021)
Improved oncological outcome after radical prostatectomy in patients staged with 68 Ga-PSMA-11 PET: a single-center retrospective cohort comparison
Eur J Nucl Med Mol Imaging. 48(4):1219-28
Impact factor: 7.6
110. Kliesch S, Schmidt S, Wilborn D, Aigner C, Albrecht W, Bedke J, Beintker M, Beyersdorff D, Bokemeyer C, Busch J, Classen J, de Wit M, Dieckmann KP, Diemer T, Dieing A, Gockel M, Göckel-Beining B, Hakenberg OW, Heidenreich A, Heinzlbecker J, Herkommer K, **Hermanns T**, Kaufmann S, Kornmann M, Kotzerke J, Krege S, Kristiansen G, Lorch A, Müller AC, Oechsle K, Ohloff T, Oing C, Otto U, Pfister D, Pichler R, Recken H, Rick O, Rudolph Y, Ruf C, Schirren J, Schmelz H, Schmidberger H, Schrader M, Schweyer S, Seeling S, Souchon R, Winter C, Wittekind C, Zengerling F, Zermann DH, Zillmann R, Albers P (2021)
Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I: Epidemiology, Classification, Diagnosis, Prognosis, Fertility Preservation, and Treatment Recommendations for Localized Stages
Urol Int. 105(3-4):169-80
Impact factor: 1.3

111. Kliesch S, Schmidt S, Wilborn D, Aigner C, Albrecht W, Bedke J, Beintker M, Beyersdorff D, Bokemeyer C, Busch J, Classen J, de Wit M, Dieckmann KP, Diemer T, Dieing A, Gockel M, Göckel-Beining B, Hakenberg OW, Heidenreich A, Heinzelbecker J, Herkommer K, **Hermanns T**, Kaufmann S, Kornmann M, Kotzerke J, Krege S, Kristiansen G, Lorch A, Müller AC, Oechsle K, Ohloff T, Oing C, Otto U, Pfister D, Pichler R, Recken H, Rick O, Rudolph Y, Ruf C, Schirren J, Schmelz H, Schmidberger H, Schrader M, Schweyer S, Seeling S, Souchon R, Winter C, Wittekind C, Zengerling F, Zermann DH, Zillmann R, Albers P (2021)
Management of Germ Cell Tumours of the Testes in Adult Patients: German Clinical Practice Guideline, PART II - Recommendations for the Treatment of Advanced, Recurrent, and Refractory Disease and Extragenital and Sex Cord/Stromal Tumours and for the Management of Follow-Up, Toxicity, Quality of Life, Palliative Care, and Supportive Therapy
Urol Int. 105(3-4):181-191
Impact factor: 1.3
112. Grogg JB, Fronzaroli JN, Oliveira P, Bode PK, Lorch A, Issa A, Beyer J, Eberli D, Sangar V, **Hermanns T**, Clarke NW, Fankhauser CD (2021)
Clinicopathological characteristics and outcomes in men with mesothelioma of the tunica vaginalis testis: analysis of published case-series data
J Cancer Res Clin Oncol;147(9):2671-2679
Impact factor: 2.8
113. Wettstein MS, David LA, Pazhepurackel C, Qureshi AA, Zisman A, Nesbitt M, Saba K, Herrera-Caceres JO, Fankhauser CD, Ahmad A, Hamilton RJ, Eberli D, Zlotta AR, Sulser T, Fleshner NE, Poyet C, Finelli A, **Hermanns T***, Kulkarni GS (2021)
Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysis
Prostate;81(5):286-294
Impact factor: 2.5

114. Seidel C, Daugaard G, Nestler T, Tryakin A, Fedyanin M, Fankhauser CD, **Hermanns T**, Aparicio J, Heinzlbecker J, Paffenholz P, Heidenreich A, De Giorgi U, Cathomas R, Lorch A, Fingerhut A, Gayer F, Bremmer F, Giannatempo P, Necchi A, Raggi D, Aurilio G, Casadei C, Hentrich M, Tran B, Dieckmann KP, Brito M, Ruf C, Mazzocca A, Vincenzi B, Stahl O, Bokemeyer C, Oing C (2021)
The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3)
World J Urol. 39(9):3407-3414
Impact factor: 2.9
115. Waisbrod S, Natsos A, Wettstein MS, Saba K, **Hermanns T**, Fankhauser CD, Müller A. (2021)
Assessment of Diagnostic Yield of Cystoscopy and Computed Tomographic Urography for Urinary Tract Cancers in Patients Evaluated for Microhematuria: A Systematic Review and Meta-analysis
JAMA Netw Open. 4(5):e218409.
Impact factor: 9.7
116. Fankhauser CD, Weber D, Müntener M, Poyet C, Sulser T, **Hermanns T** (2021)
Effectiveness of Flexible Ureterorenoscopy Versus Extracorporeal Shock Wave Lithotripsy for Renal Calculi of 5-15 mm: Results of a Randomized Controlled Trial
Eur Urol Open Sci. 25:5-10
Impact factor: 4.5
117. Saba K, Högger DC, Hötter AM, Rupp NJ, Sulser T, **Hermanns T** (2021)
Dignity of Small Renal Masses: Implications for Diagnostics and Therapy Praxis (Bern 1994). 110(10):565-570
Impact factor: n/a
118. Rüschoff JH, Ferraro DA, Muehlematter UJ, Laudicella R, **Hermanns T**, Rodewald AK, Moch H, Eberli D, Burger IA, Rupp NJ (2021)
What's behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns.
Eur J Nucl Med Mol Imaging;48(12):4042-4053.
Impact factor: 7.6

119. Fankhauser CD, Weber D, Müntener M, Poyet C, Sulser T, **Hermanns T** (2021)
Effectiveness of Flexible Ureterorenoscopy Versus Extracorporeal Shock Wave Lithotripsy for Renal Calculi of 5-15 mm: Results of a Randomized Controlled Trial
Eur Urol Open Sci. 2021 Feb 2;25:5-10.
Impact factor: 4.5
120. Lee DD, Komosa M, Sudhaman S, Leão R, Zhang CH, Apolonio JD, **Hermanns T**, Wild PJ, Klocker H, Nassiri F, Zadeh G, Diplas BH, Yan H, Gallinger S, Pugh TJ, Ramaswamy V, Taylor MD, Castelo-Branco P, Nunes NM, Tabori U. (2021)
Dual role of allele-specific DNA hypermethylation within the TERT promoter in cancer.
J Clin Invest.;131(21):e146915.
Impact factor: 13.6
121. Arvaniti E, Fricker KS, Moret M, Rupp N, **Hermanns T**, Fankhauser C, Wey N, Wild PJ, Rüschhoff JH, Claassen M. (2021)
Author Correction: Automated Gleason grading of prostate cancer tissue microarrays via deep learning.
Sci Rep.;11(1):23032.
Impact factor: 3.9
122. Martini A, Soeterik TFW, Haverdings H, Rahota RG, Checcucci E, De Cillis S, **Hermanns T**, Fankhauser CD, Afferi L, Moschini M, Mattei A, Kesch C, Heidegger I, Preisser F, Zattoni F, Marquis A, Marra G, Gontero P, Briganti A, Montorsi F, Porpiglia F, Van Basten JP, Van den Bergh RCN, Van Melick HHE, Ploussard G, Gandaglia G, Valerio M. (2022)
An Algorithm to Personalize Nerve Sparing in Men with Unilateral High-Risk Prostate Cancer.
J Urol.;207(2):350-357.
Impact factor: 6.8
123. Wettstein MS, Baxter NN, Sutradhar R, Mamdani M, Song P, Qadri SR, Bhalla G, Li K, Liu N, van der Kwast T, **Hermanns T**, Kulkarni GS. (2022)
Factors Associated with Re-Resection in T1 Bladder Cancer: Identifying Patients Who Do Not Receive Guideline-Concordant Care at the Population Level.
J Urol.;207(2):314-323.
Impact factor: 6.8

124. Wettstein MS, Baxter NN, Sutradhar R, Mamdani M, Song P, Qadri SR, Li K, Liu N, van der Kwast T, **Hermanns T**, Kulkarni GS. (2022)
Oncological benefit of re-resection for T1 bladder cancer: a comparative effectiveness study.
BJU Int; 129(2):258-268.
Impact factor: 4.4
125. Grossmann NC, Schuettfort VM, Pradere B, Rajwa P, Quhal F, Mostafaei H, Laukhtina E, Mori K, Motlagh RS, Aydh A, Katayama S, Moschini M, Fankhauser CD, **Hermanns T**, Abufaraj M, Mun DH, Zimmermann K, Fajkovic H, Haydter M, Shariat SF. (2022)
Impact of preoperative systemic immune-inflammation Index on oncologic outcomes in bladder cancer patients treated with radical cystectomy.
Urol Oncol.;40(3):106.e11-106.e19.
Impact factor: 2.3
126. Fankhauser CD, Christiansen AJ, Rothermundt C, Cathomas R, Wettstein MS, Grossmann NC, Grogg JB, Templeton AJ, Hirschi-Blickenstorfer A, Lorch A, Gillessen S, Moch H, Beyer J, **Hermanns T**. (2022)
Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours.
Br J Cancer.;126(8):1140-1144.
Impact factor: 6.8
127. Kaufmann B, Saba K, Schmidli TS, Stutz S, Bissig L, Britschgi AJ, Schaeren E, Gu A, Langenegger N, Sulser T, Eberli D, Keller EX, **Hermanns T**, Poyet C. (2022)
Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
Prostate. ;82(3):388-396.
Impact factor: 2.5
128. Gu A, Oyo L, Grossmann NC, Wettstein MS, Kaufmann B, Bieri U, Poyet C, **Hermanns T**, Sulser T, Eberli D, Keller EX. (2022)
Tumor Stent for Chronic Ureteral Obstruction: Which Are Predictors of Stent Failure?
J Endourol.;36(6):819-826.
Impact factor: 2.8

129. Wettstein MS, Baxter NN, Sutradhar R, Mamdani M, Song P, Qadri SR, Li K, Liu N, van der Kwast T, **Hermanns T**, Kulkarni GS. (2022)
Uptake of re-resection in T1 bladder cancer: An interrupted population-based time series analysis among different groups of surgeons.
Urol Oncol.;40(4):165.e1-165.e8.
Impact factor: 2.3
130. Alijaj N, Pavlovic B, Martel P, Rakauskas A, Cesson V, Saba K, **Hermanns T**, Oechslin P, Veit M, Provenzano M, Rüschoff JH, Brada MD, Rupp NJ, Poyet C, Derré L, Valerio M, Banzola I, Eberli D. (2022)
Identification of Urine Biomarkers to Improve Eligibility for Prostate Biopsy and Detect High-Grade Prostate Cancer.
Cancers (Basel).;14(5):1135.
Impact factor: 4.4
131. Fankhauser CD, Afferi L, Stroup SP, Rocco NR, Olson K, Bagrodia A, Baky F, Cazzaniga W, Mayer E, Nicol D, Islamoglu E, de Vergie S, Saoud R, Eggener SE, Nazzani S, Nicolai N, Hugar L, Sexton WJ, Matei DV, De Cobelli O, Cheaib J, Pierorazio PM, Porter J, **Hermanns T**, Hamilton RJ, Hiester A, Albers P, Clarke N, Mattei A. (2022)
Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility.
World J Urol.;40(6):1505-1512.
Impact factor: 2.9
132. Laudicella R, Rüschoff JH, Ferraro DA, Brada MD, Hausmann D, Mebert I, Maurer A, **Hermanns T**, Eberli D, Rupp NJ, Burger IA. (2022)
Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI.
Eur J Nucl Med Mol Imaging.;49(11):3917-3928.
Impact factor: 7.6
133. Grossmann NC, Schuettfort VM, Betschart J, Becker AS, **Hermanns T**, Keller EX, Fankhauser CD, Kranzbühler B. (2022)
Risk factors for concomitant positive midstream urine culture in patients presenting with symptomatic ureterolithiasis.
Urolithiasis;50(3):293-302.
Impact factor: 2.2

134. De Vargas Roditi L, Jacobs A, Rueschoff JH, Bankhead P, Chevrier S, Jackson HW, **Hermanns T**, Fankhauser CD, Poyet C, Chun F, Rupp NJ, Tschaebunin A, Bodenmiller B, Wild PJ. (2022)
Single-cell proteomics defines the cellular heterogeneity of localized prostate cancer.
Cell Rep Med.;3(4):100604.
Impact factor: 10.6
135. Pratsinis M, Fankhauser C, Pratsinis K, Beyer J, Bühner E, Cathomas R, Fischer N, **Hermanns T**, Hirschi-Blickenstorfer A, Kamradt J, Alex Kluth L, Zihler D, Mingrone W, Müller B, Nestler T, Rothschild SI, Seifert B, Templeton AJ, Terbuch A, Ufen MP, Woelky R, Gillessen S, Rothermundt C. (2022)
Metastatic Potential of Small Testicular Germ Cell Tumors: Implications for Surveillance of Small Testicular Masses.
Eur Urol Open Sci.;40:16-18.
Impact factor: 4.5
136. Schmid FA, Bausch K, Wettstein MS, Feicke A, Weltzien B, Schmid DM, Strebel RT, Poyet C, Rupp NJ, Sulser T, Seifert HH, **Hermanns T**. (2022)
Long-Term Oncological Efficacy of Retroperitoneoscopic Radical Nephrectomy of Localized Renal Cell Cancer pT1-3 (≤ 12 cm).
Clin Genitourin Cancer.;20(5):e411-e418.
Impact factor: 2.7
137. Bieri U, Buser L, Wettstein MS, Eberli D, Saba K, Moch H, **Hermanns T**, Poyet C. (2022)
Modified Immunoscore Improves Prediction of Survival Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer-A Retrospective Digital Pathology Study.
Diagnostics (Basel).;12(6):1360.
Impact factor: 3.3
138. Grogg JB, Dursun ZH, Beyer J, Eberli D, Poyet C, **Hermanns T**, Fankhauser CD. (2022)
Oncological and functional outcomes after testis-sparing surgery in patients with germ cell tumors: a systematic review of 285 cases.
World J Urol.;40(9):2293-2303.
Impact factor: 2.9

139. Bieri U, Enderlin D, Buser L, Wettstein MS, Eberli D, Moch H, **Hermanns T**, Poyet C. (2022)
Modified immunoscore improves the prediction of progression-free survival in patients with non-muscle-invasive bladder cancer: A digital pathology study.
Front Oncol.;12:964672
Impact factor: 3.3
140. Bieri U, Kranzbühler B, Seifert B, Helmchen BM, Gu A, Kaufmann B, Lavrek D, Scherer T, Wettstein MS, Poyet C, **Hermanns T**. (2022)
Is Regular Radiographic Upper Urinary Tract Imaging for Surveillance of Non-Muscle Invasive Bladder Cancer Justified?
Cancers (Basel).;14(22):5586.
Impact factor: 4.4
141. Christiansen AJ, Lobo J, Fankhauser CD, Rothermundt C, Cathomas R, Batavia AA, Grogg JB, Templeton AJ, Hirschi-Blickenstorfer A, Lorch A, Gillessen S, Moch H, Beyer J, **Hermanns T**. (2022)
Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence.
Front Oncol.;12:1056823.
Impact factor: 3.3
142. Grossmann NC, Gröbli N, Lautenbach N, Affentranger A, Eberli D, Sulser T, **Hermanns T**, Poyet C. (2023)
The Role of Additional Epididymis Resection during Hydrocelectomy: Is It of Any Benefit in Comparison to Simple Hydrocelectomy?
Urol Int.;107(4):390-395.
Impact factor: 1.3
143. Neuenschwander A, Lonati C, Antonelli L, Papachristofilou A, Cathomas R, Rothermundt C, Templeton AJ, Gulamhusein A, Fischer S, Gillessen S, **Hermanns T**, Lorch A, Mattei A, Fankhauser CD. (2023)
Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review.
Eur Urol Focus. ;9(3):541-546.
Impact factor: 5.6

144. Grossmann NC, Ardizzone D, **Hermanns T**, Keller EX, Fankhauser CD. (2023)
Is conservative management safe in patients with acute ureterolithiasis and perirenal stranding?
Urolithiasis.;51(1):40.
Impact factor: 2.2
145. Fischer S, Rothermundt C, Stalder O, Terbuch A, **Hermanns T**, Zihler D, Müller B, Fankhauser CD, Hirschi-Blickenstorfer A, Seifert B, Kluth LA, Ufe MP, Mingrone W, Templeton AJ, Fischer N, Rothschild S, Woelky R, Gillessen S, Cathomas R. (2023)
The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study.
Eur Urol Open Sci.;50:57-60.
Impact factor: 4.5
146. Martini A, Wever L, Soeterik TFW, Rakauskas A, Fankhauser CD, Grogg JB, Checcucci E, Amparore D, Haiquel L, Rodriguez-Sanchez L, Ploussard G, Qiang P, Affentranger A, Marquis A, Marra G, Ettala O, Zattoni F, Falagario UG, De Angelis M, Kesch C, Apfelbeck M, Al-Hammouri T, Kretschmer A, Kasivisvanathan V, Preisser F, Lefebvre E, Olivier J, Radtke JP, Briganti A, Montorsi F, Carrieri G, Moro FD, Boström P, Jambor I, Gontero P, Chiu PK, John H, Macek P, Porpiglia F, **Hermanns T**, van den Bergh RCN, van Basten JA, Gandaglia G, Valerio M. (2023)
Unilateral Pelvic Lymph Node Dissection in Prostate Cancer Patients Diagnosed in the Era of Magnetic Resonance Imaging-targeted Biopsy: A Study That Challenges the Dogma.
J Urol.;210(1):117-127.
Impact factor: 6.8
147. Notarfrancesco M, Fankhauser CD, Lorch A, Ardizzone D, Helnwein S, Hoch D, **Hermanns T**, Thalmann G, Beyer J. (2023)
Perioperative complications and oncological outcomes of post-chemotherapy retroperitoneal lymph node dissection in patients with germ cell cancer at two high-volume university centres in Switzerland - a retrospective chart review.
Swiss Med Wkly.;153:40053.
Impact factor: 1.9

148. Muehlematter UJ, Schweiger L, Ferraro DA, **Hermanns T**, Maurer T, Heck MM, Rupp NJ, Eiber M, Rauscher I, Burger IA. (2023)
Development and external validation of a multivariable [68Ga]Ga-PSMA-11 PET-based prediction model for lymph node involvement in men with intermediate or high-risk prostate cancer.
Eur J Nucl Med Mol Imaging.;50(10):3137-3146.
Impact factor: 7.6
149. Bieri U, Kranzbühler B, Wettstein MS, Fankhauser CD, Kaufmann BP, Seifert B, Bode PK, Poyet C, Lenggenhager D, **Hermanns T**. (2023)
Limited Value of Bladder Wash Cytology During Follow-Up of Patients With Non-muscle Invasive Bladder Cancer.
Cureus.;15(6):e40283.
Impact factor: 1.3
150. Poyet C, Scherer TP, Kunz M, Wanner M, Korol D, Rizzi G, Kaufmann B, Rohrmann S, **Hermanns T**. (2023)
Retrospective analysis of the uptake of active surveillance for low-risk prostate cancer in Zurich, Switzerland.
Swiss Med Wkly.;153:40103.
Impact factor: 1.9
151. Hoch D, Helnwein S, Adrizzzone D, Lorch A, Fankhauser C, **Hermanns T**, Thalmann G, Beyer J. (2023)
No Survival Differences among Germ-Cell Cancer Patients from Urban and Rural Areas.
Oncol Res Treat.;46(10):433-437.
Impact factor: 2.8
152. Speicher P, Fankhauser CD, Lorch A, Ardizzzone D, Helnwein S, Hoch D, **Hermanns T**, Beyer J, Akhoundova D. (2023)
Excellent survival in relapsed stage I testicular cancer.
BMC Cancer. ;23(1):870.
Impact factor: 3.4

153. Zhong Q, Sun R, Aref AT, Noor Z, Anees A, Zhu Y, Lucas N, Poulos RC, Lyu M, Zhu T, Chen GB, Wang Y, Ding X, Rutishauser D, Rupp NJ, Rueschoff JH, Poyet C, **Hermanns T**, Fankhauser C, Rodríguez Martínez M, Shao W, Buljan M, Neumann JF, Beyer A, Hains PG, Reddel RR, Robinson PJ, Aebersold R, Guo T, Wild PJ. (2023)
Proteomic-based stratification of intermediate-risk prostate cancer patients.
Life Sci Alliance.;7(2):e202302146.
Impact factor: 2.9
154. von der Grün J, Ahmadsei M, Breyer I, Britschgi C, Eberli D, **Hermanns T**, Mangana J, Petrowsky H, Ramelyte E, Roth P, Schär G, Opitz I, Weller M, Wicki A, Witzel I, Balermipas P, Guckenberger M. (2023)
Patient recruitment into clinical studies of solid malignancies during the COVID-19 pandemic in a tertiary cancer center.
Neoplasia.;46:100946.
Impact factor: 7.7
155. Marra G, Rajwa P, Filippini C, Ploussard G, Montefusco G, Puche-Sanz I, Olivier J, Zattoni F, Moro FD, Magli A, Dariane C, Affentranger A, Grogg JB, **Hermanns T**, Chiu PK, Malkiewicz B, Kowalczyk K, Van den Bergh RCN, Shariat SF, Bianchi A, Antonelli A, Gallina S, Berchiche W, Sanchez-Salas R, Cathelineau X, Afferi L, Fankhauser CD, Mattei A, Karnes RJ, Scuderi S, Montorsi F, Briganti A, Deandreis D, Gontero P, Gandaglia G. (2024)
The Prognostic Role of Preoperative PSMA PET/CT in cNOMO pN+ Prostate Cancer: A Multicenter Study.
Clin Genitourin Cancer. ;22(2):244-251.
Impact factor: 2.7
156. Martini A, Wever L, Soeterik TFW, Rakauskas A, Fankhauser CD, Grogg JB, Checcucci E, Amparore D, Haiquel L, Rodriguez-Sanchez L, Ploussard G, Qiang P, Affentranger A, Marquis A, Marra G, Ettala O, Zattoni F, Falagario UG, De Angelis M, Kesch C, Apfelbeck M, Al-Hammouri T, Kretschmer A, Kasivisvanathan V, Preisser F, Lefebvre E, Olivier J, Radtke JP, Carrieri G, Moro FD, Boström P, Jambor I, Gontero P, Chiu PK, John H, Macek P, Porpiglia F, **Hermanns T**, van den Bergh RCN, van Basten JA, Gandaglia G, Valerio M. (2024)
An updated model for predicting side-specific extraprostatic extension in the era of MRI-targeted biopsy.
Prostate Cancer Prostatic Dis.;27(3):520-524.
Impact factor: 5.8

157. **Hermanns T**, Wettstein MS, Kaufmann B, Lautenbach N, Kaufmann E, Saba K, Schmid FA, Hötter AM, Müntener M, Umbehre M, Poyet C. (2024) BioPrev-C - development and validation of a contemporary prostate cancer risk calculator. Front Oncol.;14:1343999.
Impact factor: 3.3
158. Pavlovic B, Bräutigam K, Dartiguenave F, Martel P, Rakauskas A, Cesson V, Veit M, Oechslin P, Gu A, **Hermanns T**, Saba K, Poyet C, Hötter AM, Rupp NJ, Valerio M, Derré L, Eberli D, Banzola I. (2024) Urine biomarkers can predict prostate cancer and PI-RADS score prior to biopsy. Sci Rep.;14(1):18148.
Impact factor: 3.9
159. Fankhauser CD, Wettstein MS, Christiansen AJ, Rothermundt C, Cathomas R, Kaufmann E, Sigg S, Templeton AJ, Hirschi-Blickenstorfer A, Lorch A, Gillissen S, Beyer J, **Hermanns T**. (2024) Cut-offs for relapse detection in men with stage I testicular germ cell tumors during active surveillance within a prospective multicentre cohort study using either raw or housekeeper normalized miR-371a-3p serum levels. Urol Oncol.;42(12):455.e9-455.e13.
Impact factor: 2.3
160. Marra G, Lesma F, Montefusco G, Filippini C, Olivier J, Affentranger A, Grogg JB, **Hermanns T**, Afferi L, Fankhauser CD, Mattei A, Malkiewicz B, Scuderi S, Barletta F, Gallina S, Antonelli A, Zattoni F, Dal Moro F, Lieke W, Soeterik T, van den Bergh RCN, Rajwa P, Shariat SF, Rodriguez-Sanchez L, Nicoletti R, Campi R, Ahmed M, Jeffrey Karnes R, Ladurner M, Heidegger I, Briganti A, Gontero P, Gandaglia G. (2024) Observation With or Without Subsequent Salvage Therapy for Pathologically Node-positive Prostate Cancer With Negative Conventional Imaging: Results From a Large Multicenter Cohort. Eur Urol Open Sci.;68:32-39.
Impact factor: 4.5

161. Kaufmann E, Aeppli S, Arnold W, Balermipas P, Beyer J, Bieri U, Cathomas R, de Bari B, Dressler M, Engeler DS, Erdmann A, Gallina A, Gomez S, Guckenberger M, Herrmann TRW, **Hermanns T**, Ilaria L, John H, Kessler TM, Klein J, Laouiti M, Lauffer D, Mattei A, Müntener M, Nguyen D, Niederberger P, Papachristofilou A, Prause L, Reinhardt K, Salati E, Sèbe P, Shelan M, Strebel R, Templeton AJ, Vogl U, Wettstein MS, Zihler D, Zilli T, Zwahlen D, Roth B, Fankhauser C. (2024)
Follow-up strategies after trimodal treatment for muscle-invasive bladder cancer: a systematic review.
World J Urol.;42(1):527.
Impact factor: 2.9
162. Pedrazzi NE, Schweizer R, Klein HJ, Steiner S, Vonlanthen R, **Hermanns T**, Schneider D, Giovanoli P, Plock JA. (2025)
Versatility of the Anterolateral Thigh Flap for Abdominal Wall Reconstruction.
Plast Reconstr Surg Glob Open.;13(1):e6433.
Impact factor: 1.8
163. Marra G, Barletta F, Scuderi S, Montefusco G, Olivier J, Affentranger A, Grogg JB, **Hermanns T**, Afferi L, Fankhauser C, Mattei A, Malkiewicz B, Bianchi A, Antonelli A, Zattoni F, Dal Moro F, Wever L, Soeterik TFW, Van Den Bergh RCN, Rajwa P, Shariat SF, Sanchez-Salas R, Rodriguez-Sanchez L, Nicoletti R, Campi R, Ahmed M, Karnes RJ, Heidegger I, Briganti A, Montorsi F, Gontero P, Gandaglia G. (2025)
Adjuvant Radiation Therapy or Observation With or Without Early Salvage Radiation Therapy for Men With Node-Positive Prostate Cancer After Surgery and Negative Preoperative Conventional Imaging: A Multicenter Study.
J Urol.;213(6):702-712.
Impact factor: 6.8
164. Bausch K, Speich B, Vogt DR, Hemkens LG, Dreher M, Kwiatkowski M, Subotic S, Ardelt P, Bossard P, **Hermanns T**, Bruni N, Wyler S, Prause L, Merz SC, Engesser C, Roth J, Widmer AF, Seifert HH. (2025)
Single-dose Versus 3-day Antimicrobial Prophylaxis in Transurethral Resection or Photoselective Vaporization of the Prostate: A Multicenter, Randomized, Placebo Controlled Trial (CITrUS Trial).
Eur Urol Focus; S2405-4569(25)00254-8.
Impact factor: 5.6

165. Grossmann NC, Funk L, Fankhauser CD, Beyer J, Lorch A, **Hermanns T**. (2026)
Improved quality of care for testicular germ cell cancer patients by the implementation of an interdisciplinary testis cancer clinic.
Urol Oncol.;44(1):72.e9-e14.
Impact factor: 2.3
166. Kaufmann E, Aeppli S, Affentranger A, Arnold N, Arnold W, Aschwanden F, Balermipas P, Beyer J, Bieri U, Boormanns J, Cathomas R, Bari B, Dressler M, Engeler DS, Erdmann A, Gallina A, Gomez S, Guckenberger M, Herrmann T, **Hermanns T**, Lucca I, John H, Kessler TM, Klein J, Laouiti M, Lauffer D, Lerner SP, Mattei A, Müntener M, Nguyen D, Niederberger P, Papachristofilou A, Prause L, Putora PM, Reinhardt K, Salati E, Sèbe P, Shelan M, Sigg S, Strebel RT, Templeton AJ, Vogl U, Wettstein MS, Wyler S, Zihler D, Zilli T, Zwahlen D, Roth B, Fankhauser CD. (2026)
Interdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancer.
Bladder Cancer.;12(1): 23523735251410823.
Impact factor: 1.2
167. Al-Nader M, Kesch C, Mahmoud O, Hadaschik BA, Fichtner J, Carl G, Feick G, Burchardt M, Zimmermanns V, Prause L, Polat B, Blana A, Horstmann M, Saar M, Miglierini P, Almansur K, Hefermehl L, Porres D, Peters I, Wiens K, Palisaar RJ, Winter A, Neisius A, Kunzmann EM, Harke NN, Bolenz C, Albarghouth MH, Manka L, Kramer M, Luger F, Knoll T, Pfitzenmaier J, Brock M, Schittko J, Sommer JP, Reichert M, Lenart S, Huber P, Hijazi S, Calderaro A, **Hermanns T**, Tonhauser J, Kowalski C, Sibert NT. (2026)
Patient-reported outcomes: active surveillance vs radical therapies in low-risk prostate cancer.
BJU Int. 2026 Feb 16.
Impact factor: 4.4
168. Gillessen S, Gobat K, Cathomas R, Fischer N, Pereira Mestre R, **Hermanns T**, Rothschild SI, Mach N, Mingrone W, Ciriolo M, Müller B, Erdmann A, Schär C, Mamot C, Bohanes P, Omlin A, Bastian S, Ribi K, Mazzucchelli L, Barizzi J, Horvath LG, Scheinberg T, Mellor R, Schär S, Lin HM, Lim R, Pollak M, Turco F, Rothermundt C (2026)
Enzalutamide Plus Metformin Versus Enzalutamide Alone in Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 2 Trial (SAKK 08/14).
Eur Urol Oncol. 2026
Impact factor: 9.3

2. Editorials

169. Poyet C, **Hermanns T** (2016)
Prostate cancer risk calculators: still much work ahead.
BJU Int. 118(5):670-671
Impact factor: 4.4
170. **Hermanns T**, Poyet C (2017)
The next generation of prostate cancer risk calculators.
Eur Urol. 72(6):897-898
Impact factor: 25.2

3. Case reports

171. Zeh N, Wild PJ, Bode P, Moch H, Kristiansen G, Sulser T, **Hermanns T** (2013)
Retroperitoneal teratoma with somatic malignant transformation: A papillary renal cell carcinoma in a germ cell tumour metastasis following platinum-based chemotherapy.
BMC Urol. 13:9
Impact factor: 1.9
172. Poyet C, Grubhofer F, Zimmermann M, Sulser T, **Hermanns T** (2013)
Therapy-resistant nephrolithiasis following renal artery coil embolization.
BMC Urol. 13:29
Impact factor: 1.9
173. Fankhauser CD, **Hermanns T**, Hasse B, Rancic Z
Excessive wound fluid discharge during retroperitoneal negative pressure wound therapy
Ann Vasc Surg. 43:314.e1-314.e3
Impact factor: 1.6

4. Reviews

174. Seifert HH, **Hermanns T**, Sulser T (2008)
GreenLight laser vaporisation of the prostate for treatment of benign prostatic hyperplasia. Development and significance.
Die Urologie. 47(8): 964-8
Impact factor: 0.4
175. Fankhauser CD, Kranzbühler B, Poyet C, **Hermanns T**, Sulser T, Steurer J (2015)
Long-term adverse effects of extracorporeal shock-wave lithotripsy for nephro- and ureterolithiasis: a systematic review.
Urology. 85(5): 991-1006
Impact factor: 2.0
176. Kozomara M, **Hermanns T**, Poyet C (2016)
Male Urinary Incontinence – A Taboo Issue.
Praxis. 105(5): 269-77
Impact factor: n/a
177. Fankhauser CD, Poyet C, Kroeze SGC, Kranzbühler B, Schüler HIG, Guckenberger M, Kaufmann PA, **Hermanns T**, Burger IA. (2018)
Current and potential future role of PSMA-PET in patients with castration-resistant prostate cancer.
World J Urol. 37(3):457-467
Impact factor: 2.9
178. Beyer J, Berthold D, Bode PK, Cathomas R, Fankhauser CD, Fischer S, Gillessen S, Gross T, **Hermanns T**, Honecker F, Lorch A, Omlin A, Papachristofilou A, Roth B, Rothermundt C, Seiler R, Spahn M, Stenner F, Bührer E.
Swiss germ-cell cancer consensus recommendations (2021)
Swiss Med Wkly. 2021 Aug 23;151(33-34)
Impact factor: 1.9

5. Book Chapter

179. **Hermanns T**, Sulser T
Interventional treatment: Prostate Laser.
Benign prostatic hyperplasia and lower urinary tract symptoms in man,
Oxford Urology Library, editors: A. Bachmann & JJMCH de la Rosette,
Oxford University Press 2012
180. **Hermanns T**, Kuk C, Zlotta AR
Prostate cancer: Clinical Presentation, Diagnosis and Staging.
Urological Oncology, editors: VH Nargund, D Raghavan, HM Sandler
Springer Verlag, London 2015

6. Proceedings

181. **Hermanns T**, Sulser T, Fatzer M, Baumgartner MK, Rey JM, Sigrist MW,
Seifert HH
(2008)
Intra-operative power measurement of laser fibers during photoselective
vaporization of the prostate using the 80W-KTP-Greenlight laser.
Proceedings of SPIE, Vol. 6842; Progress in Biomedical Optics and Imaging
Vol. 9, No. 1; Photonic Therapeutics and Diagnostics IV, 684211
182. **Hermanns T**, Sulser T, Hefermehl LJ, Strebel DD, Michel MS, Mütener M,
Meier AH, Seifert HH (2009)
Loss of Power Output and Laser Fibre Degradation during 120 Watt
Lithium-Triborate HPS Laser Vaporisation of the Prostate.
Proceedings of SPIE, Vol. 7161; Progress in Biomedical Optics and Imaging
Vol. 10, No. 1; Photonic Therapeutics and Diagnostics V, 71611-1
183. Gross O, Sulser T, Hefermehl LJ, Strebel DD, Largo R, Mortezaei A, Poyet
C, Eberli D, Zimmerman M, Müller A, Michel MS, Mütener M, Seifert HH,
Hermanns T (2011)
Ablative efficiency of lithium-triborate laser vaporisation and conventional
transurethral resection of the prostate: A comparison using transrectal
three-dimensional ultrasound volumetry.
Proceedings of SPIE, Vol. 7883; Progress in Biomedical Optics and Imaging
Vol. 12, No. 1; Photonic Therapeutics and Diagnostics VII, 78831-1

184. Kranzbühler B, Gross O, Fankhauser CD, Hefermehl LJ, Poyet C, Largo R, Müntener M, Seifert HH, Zimmermann M, Sulser T, Müller A, **Hermanns T** (2012)
Tissue ablation after 120W greenlight laser vaporization and bipolar plasma vaporization of the prostate. A comparison using transrectal three-dimensional ultrasound volumetry.
Proceedings of SPIE, Vol. 8207; Progress in Biomedical Optics and Imaging Vol.; Photonic Therapeutics and Diagnostics VIII, 820783-1

7. Letters

185. Fankhauser CD, Grossmann NC, Beyer J, **Hermanns T**. (2018)
Re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262-70.
Eur Urol. 73(4):e94-e95
Impact factor: 25.2